Investment Analysts’ Weekly Ratings Updates for Protagonist Therapeutics (PTGX)

Protagonist Therapeutics (NASDAQ: PTGX) recently received a number of ratings updates from brokerages and research firms:

• 10/23/2026 – Protagonist Therapeutics was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 10/21/2026 – Protagonist Therapeutics had its price target raised by TD Cowen from $155.00 to $160.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Protagonist Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/12/2026 – Protagonist Therapeutics is now covered by UBS Group. They set a “buy” rating and a $184.00 price target on the stock.
• 10/12/2026 – Protagonist Therapeutics was upgraded by UBS Group to “strong-buy”.
• 10/12/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Leerink Partners. They now have a $190.00 price target on the stock, up from $150.00.
• 10/10/2026 – Protagonist Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/8/2026 – Protagonist Therapeutics was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 9/1/2026 – Protagonist Therapeutics had its price target raised by Barclays from $153.00 to $180.00. They now have an “overweight” rating on the stock.
• 9/1/2026 – Protagonist Therapeutics had its price target raised by BMO Capital Markets from $178.00 to $190.00. They now have an “outperform” rating on the stock.
• 8/31/2026 – Protagonist Therapeutics had its price target raised by Citigroup from $175.00 to $182.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Citigroup.
• 8/31/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Wolfe Research.
• 8/31/2026 – Protagonist Therapeutics had its price target raised by HC Wainwright from $167.00 to $170.00. They now have a “buy” rating on the stock.

Insider Activity at Protagonist Therapeutics

In other news, CFO Asif Ali sold 58,629 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the sale, the chief financial officer directly owned 59,003 shares in the company, valued at approximately $8,365,445.34. The trade was a 49.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinsesh Patel sold 7,278 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $144.10, for a total value of $1,048,759.80. Following the completion of the transaction, the chief executive officer owned 522,968 shares of the company’s stock, valued at $75,359,688.80. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 283,629 shares of company stock worth $41,443,786 in the last three months. 5.19% of the stock is owned by insiders.

Protagonist Therapeutics, Inc is a biopharmaceutical company focused on discovering and developing peptide-based medicines for immune-mediated and hematologic diseases. The company uses its proprietary peptide technology platform to design therapies intended to act on specific biological pathways and receptors.

Its leading program is icotrokinra, also known as JNJ-2113, an oral, targeted inhibitor of the interleukin-23 receptor being developed in collaboration with Janssen Pharmaceuticals for inflammatory and immune-mediated conditions, including psoriasis and inflammatory bowel diseases.